The Xarelto products liability litigation accuses the manufacturer of the drug of failing to fully study or share information about the dangers of the medicine. Many other patients have filed similar claims in the consolidated litigation alleging they suffered internal bleeding after taking the medicine as prescribed.

Plaintiff James M. recently added his claim to this litigation. James alleges that the manufacturers of the Xarelto medication knew or should have known about the significant risks but failed to disclose these to the medical community or to the public, leaving patients at risk.

The plaintiff in the Xarelto products liability litigation says he used Xarelto, a popular medication that is prescribed to treat deep vein thrombosis in patients who have been diagnosed with nonvalvular atrial fibrillation. Xarelto is given to reduce the risk of stroke and systemic embolism and can also be given for the purposes of prophylaxis of DVT, for those patients going through knee and hip replacement surgery or to reduce the risk of PE or DVT.

The Xarelto products liability litigation says that the defendants fraudulently or negligently represented to the medical and health care community that Xarelto had been tested and was found to be both effective and safe for its indicated use.

Plaintiffs in the Xarelto MDL claim the defendants concealed their knowledge about the defects of Xarelto from the plaintiff, the public, the medical community and the Food and Drug Administration (FDA). The plaintiffs say that the representations made by defendants that the medication was effective as well as safe caused significant harm.

The defendants in the Xarelto products liability litigation are accused of improperly and negligently failing to perform appropriate tests on humans during the clinical trials for Xarelto. A properly conducted Xarelto study could have provided critical safety information to patients and doctors about the dangers of the blood thinner, claims the lawsuit.

Some of the most serious side effects named in the Xarelto products liability litigation include life-threatening internal bleeding, which can contribute to physical pain and mental anguish, diminished quality of life and severe personal injuries that are lasting in nature.

The Xarelto products liability litigation says that the defendants concealed their knowledge about the dangers of these defects in order to focus on profits.

James says he began taking Xarelto after it was prescribed to him by his physician for the treatment of atrial fibrillation in October 2016. He says he continued to use Xarelto from the end of October through Nov. 18, 2016.

James says he experienced a gastrointestinal bleed around Nov. 8, 2016 and alleges that this caused him severe pain and suffering as a result of the life-threatening nature.

The plaintiff says that he sustained critical injuries as a result of this life-threatening bleed which could have been avoided had he known about the serious risks associated with Xarelto.

The Xarelto Products Liability Lawsuit is Case No. 2:18-cv-10527-EEF-MBN, filed in the U.S. District Court for the Eastern District of Louisiana.